In a 45-year-old woman not taking any additional medications who is experiencing insomnia and tachycardia, what are the possible causes and recommended treatments?

Differential Diagnosis and Immediate Evaluation

In a 45-year-old woman with insomnia and heart racing, the most critical first step is to rule out hyperthyroidism, which can present with both symptoms and requires urgent evaluation with TSH and free T4 levels. 1

Key Causes to Evaluate

The combination of sleeplessness and tachycardia in a middle-aged woman warrants systematic evaluation for:

Primary Medical Causes

• Hyperthyroidism - Most important to exclude given the symptom constellation
• Cardiac arrhythmias - Particularly atrial fibrillation or supraventricular tachycardia
• Anxiety disorders - Common trigger for both symptoms 2
• Perimenopausal hormonal changes - Relevant for this age group
• Anemia - Can cause both fatigue and compensatory tachycardia

Substance-Related Causes

• Caffeine excess - Including hidden sources in medications 1
• Over-the-counter medications - Decongestants containing pseudoephedrine or phenylpropanolamine 1
• Nicotine use - Either smoking or nicotine replacement products 1

Primary Sleep Disorders

• Sleep apnea - Should be screened for, especially if there are witnessed apneas or excessive daytime sleepiness 3
• Restless legs syndrome - Can cause both sleep disruption and sensation of heart racing 3

Diagnostic Workup

Obtain focused history on:

• Timing of symptoms (sleep onset vs. maintenance difficulty)
• Heat intolerance, weight changes, tremor (thyroid symptoms)
• Palpitation characteristics and triggers
• All substances including caffeine, supplements, OTC medications
• Menstrual pattern changes
• Witnessed snoring or breathing pauses
• Mood symptoms and stressors

Essential laboratory evaluation:

• TSH and free T4
• Complete blood count (for anemia)
• ECG if palpitations are prominent

Treatment Approach

First-Line Treatment

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated as first-line treatment for all patients with chronic insomnia, regardless of the underlying cause. 4 This is a strong recommendation based on moderate-quality evidence and applies even when comorbid conditions are present 2.

CBT-I Components

CBT-I combines multiple evidence-based interventions 4:

• Sleep restriction therapy - Limiting time in bed to actual sleep time
• Stimulus control - Reassociating bed with sleep only
• Cognitive therapy - Addressing dysfunctional beliefs about sleep
• Relaxation techniques - Progressive muscle relaxation, guided imagery 1
• Sleep hygiene education - Though not effective alone, useful as part of comprehensive approach 2

Digital CBT-I is an acceptable alternative when in-person therapy is unavailable, with equivalent efficacy 4, 5.

Behavioral Interventions to Implement Immediately

While arranging CBT-I, implement these evidence-based strategies 1:

• Maintain consistent wake time daily, regardless of sleep obtained
• Avoid daytime napping (or limit to 30 minutes before 2 PM)
• Eliminate caffeine, nicotine, and alcohol
• Avoid heavy exercise within 2 hours of bedtime
• Use bedroom only for sleep and sex
• Leave bedroom if unable to fall asleep within 20 minutes

Pharmacological Treatment

Pharmacotherapy should only be considered if CBT-I alone is unsuccessful or while CBT-I is being arranged. 4 This is a weak recommendation based on low-quality evidence, emphasizing the need for shared decision-making.

Medication Selection Algorithm

For short-term use (≤4 weeks) when pharmacotherapy is necessary 2, 6:

First-line options:

• Short-intermediate acting benzodiazepine receptor agonists: zolpidem, eszopiclone, zaleplon, or temazepam 2
• Orexin receptor antagonists (daridorexant, suvorexant): Particularly effective for sleep maintenance; can be used up to 3 months 7, 5
• Ramelteon (melatonin receptor agonist): Safer profile but limited effectiveness 2, 8

Second-line if first-line unsuccessful:

• Low-dose doxepin (sedating antidepressant): 3-6 mg dose; FDA-approved for insomnia 4, 7, 9
• Trazodone: Most commonly prescribed off-label; effective for sleep initiation and maintenance with low abuse potential 3

Critical Prescribing Considerations

Start at the lowest effective dose and use the following approach 2:

• Intermittent dosing (3 nights per week) or as-needed rather than nightly
• Combine with CBT-I whenever possible for better long-term outcomes 2
• Reassess every few weeks initially, then every 6 months due to high relapse rates 2
• Taper when conditions allow, facilitated by concurrent CBT-I 2

Medications to AVOID

Do not use 2, 5:

• Over-the-counter antihistamines (diphenhydramine, doxylamine) - except doxylamine for up to 4 weeks only 8
• Barbiturates or chloral hydrate
• Antipsychotics (quetiapine, olanzapine) - unless treating comorbid condition
• Fast-release melatonin
• Herbal supplements (valerian) - insufficient efficacy and safety data

Special Considerations for This Patient

Age-Specific Factors

At 45 years, perimenopausal symptoms may contribute. Hormonal fluctuations affect sleep architecture and increase insomnia vulnerability in women 10. Women show greater cognitive-emotional arousal and stress-related sleep reactivity than men 10.

Addressing Tachycardia

If tachycardia persists after treating underlying causes:

• Beta blockers may help both heart rate and anxiety-related insomnia symptoms 1
• However, beta blockers alone are often ineffective for insomnia and may cause hypotension 11
• Treat the underlying cause rather than symptomatically managing tachycardia

Common Pitfalls to Avoid

1. Starting medication without attempting CBT-I first - This violates guideline recommendations and misses the most effective long-term treatment 4

2. Prescribing benzodiazepines or Z-drugs for chronic nightly use - Associated with dependence, cognitive impairment, falls, and potentially increased dementia risk 7

3. Relying on sleep hygiene education alone - Insufficient evidence for efficacy as monotherapy 2

4. Missing treatable comorbid conditions - Particularly thyroid disease, sleep apnea, or mood disorders 1, 3

5. Failing to reassess regularly - Insomnia has high relapse rates requiring ongoing monitoring 2

Treatment Timeline

• Immediate: Rule out hyperthyroidism and other medical causes; implement basic behavioral strategies
• Week 1-2: Initiate CBT-I (in-person or digital)
• Week 2-4: If inadequate response to CBT-I alone, consider adding short-term pharmacotherapy with shared decision-making
• Month 1-3: Continue CBT-I; taper medication if used
• Month 6+: Reassess for relapse; reinforce behavioral strategies

The goal is durable improvement in sleep quality and daytime functioning, which is best achieved through CBT-I rather than chronic medication use. 2, 4